Peer-reviewed veterinary case report
Feline oral cancer and potential treatment with cox inhibitors
By DiBernardi, Lisa et al.·Published in Prostaglandins, leukotrienes, and essential fatty acids·2007·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment.
- Species:
- cat
Plain-English summary
A group of cats with oral squamous cell carcinoma (OSCC), a serious type of mouth cancer, was studied to see if a medication called piroxicam could help. Researchers found that a significant number of the cancer samples showed high levels of a protein called cox-2, which piroxicam targets. When given at a dose of 0.3 mg/kg, piroxicam reached effective levels in the cats' blood and had a similar effect as in healthy cats. This information is useful for planning future treatments for cats suffering from this aggressive cancer.
People also search for: cat mouth cancer treatment · piroxicam for feline cancer · oral squamous cell carcinoma in cats
Abstract
Oral squamous cell carcinoma (OSCC) is associated with high morbidity and mortality. A potential target for OSCC treatment is cyclooxygenase-2 (cox-2). Pet cats with naturally occurring OSCC may offer the opportunity to study anticancer activity of cox inhibitors. Cox-2 expression in feline OSCC was determined by immunohistochemistry. High intensity cox-2 immunoreactivity was detected in 6 of 34 (18%) feline OSCC samples. Weak immunoreactivity was noted in 22 OSCCs and in epithelial cells from oral mucosa of clinically normal cats. Pharmacokinetics of a cox inhibitor (piroxicam, 0.3 mg/kg) were studied in carcinoma-bearing cats to confirm a dose for follow-up trials. The average peak serum piroxicam concentration (948 ng/ml, which inhibited cox-2 activity) and serum half-life (15.9 h) were similar to that in normal cats. These results provide information (cox-2 expression as an inclusion criteria, 0.3 mg/kg daily piroxicam) for the design of follow-up trials of cox inhibitor treatment in pet cats with OSCC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17383864/